{"id":24433,"date":"2019-11-08T09:00:20","date_gmt":"2019-11-08T08:00:20","guid":{"rendered":"https:\/\/www.icscyl.com\/mileon\/?p=24433"},"modified":"2019-11-07T23:58:13","modified_gmt":"2019-11-07T22:58:13","slug":"sesion-bibiografica-linagliptina-en-erc-y-otros-viejos-conocidos-sulfonilureas-y-metformina","status":"publish","type":"post","link":"https:\/\/www.icscyl.com\/mileon\/sesiones-bibliograficas\/2019-11-08\/sesion-bibiografica-linagliptina-en-erc-y-otros-viejos-conocidos-sulfonilureas-y-metformina\/","title":{"rendered":"Sesi\u00f3n bibiogr\u00e1fica: linagliptina en ERC y otros viejos conocidos (sulfonilureas y metformina)"},"content":{"rendered":"\n<div class=\"wp-block-image\"><figure class=\"alignright is-resized\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/statics-cuidateplus.marca.com\/sites\/default\/files\/styles\/natural\/public\/diabetes.jpg?itok=bimP9Qh2\" alt=\"Resultado de imagen de diabetes\" width=\"237\" height=\"119\"\/><\/figure><\/div>\n\n\n\n<p>La sesi\u00f3n bibliogr\u00e1fica de hace dos semanas fue presentada por el Dr. Nistal que realiz\u00f3 una revisi\u00f3n cr\u00edt\u00edca sobre la utilidad de la linagliptina en pacientes con enfermedad renal cr\u00f3nica, as\u00ed como datos de eficacia y seguridad de metformina en esta poblaci\u00f3n de pacientes, as\u00ed como de otros f\u00e1rmacos menos utilizados actualmente como las sulfonilureas, que fueron comentados en los siguientes art\u00edculos:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk<\/li><li>Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function<\/li><li>Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes<\/li><\/ul>\n\n\n\n<p>A continuaci\u00f3n repas\u00f3 otro trabajo publicado en NEJM titulado \u00abDapaglifozin in patients with heart failure and reduced ejection fraction\u00bb<\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.icscyl.com\/mileon\/wp-content\/uploads\/2019\/11\/Dr-Nistal-sesbibl-Oct19.zip\">Dr-Nistal-sesbibl-Oct19<\/a><a href=\"https:\/\/www.icscyl.com\/mileon\/wp-content\/uploads\/2019\/11\/Dr-Nistal-sesbibl-Oct19.zip\" class=\"wp-block-file__button\" download>Descarga<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>La sesi\u00f3n bibliogr\u00e1fica de hace dos semanas fue presentada por el Dr. Nistal que realiz\u00f3 una revisi\u00f3n cr\u00edt\u00edca sobre la utilidad de la linagliptina en pacientes con enfermedad renal cr\u00f3nica, as\u00ed como datos de eficacia y seguridad de metformina en esta poblaci\u00f3n de pacientes, as\u00ed como de otros f\u00e1rmacos menos utilizados actualmente como las sulfonilureas, [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[722],"tags":[958],"class_list":["post-24433","post","type-post","status-publish","format-standard","hentry","category-sesiones-bibliograficas","tag-nistal"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts\/24433","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/comments?post=24433"}],"version-history":[{"count":0,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts\/24433\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/media?parent=24433"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/categories?post=24433"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/tags?post=24433"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}